Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Investment analysts at Wedbush increased their Q1 2025 EPS estimates for shares of Sage Therapeutics in a report released on Wednesday, November 20th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of ($1.31) per share for the quarter, up from their prior estimate of ($1.38). Wedbush has a "Neutral" rating and a $8.00 price objective on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.50) per share. Wedbush also issued estimates for Sage Therapeutics' Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.83) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($0.79) EPS and FY2028 earnings at ($0.29) EPS.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The company had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. During the same quarter last year, the company posted ($2.81) EPS. The company's quarterly revenue was up 337.1% compared to the same quarter last year.
SAGE has been the topic of a number of other research reports. TD Cowen reduced their target price on Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating for the company in a report on Thursday. Truist Financial reduced their price objective on Sage Therapeutics from $13.00 to $8.00 and set a "hold" rating for the company in a research note on Wednesday, October 30th. JPMorgan Chase & Co. reduced their price target on shares of Sage Therapeutics from $12.00 to $10.00 and set a "neutral" rating for the company in a research report on Tuesday, August 6th. HC Wainwright restated a "neutral" rating and set a $14.00 price objective on shares of Sage Therapeutics in a report on Wednesday, November 20th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $12.83.
Check Out Our Latest Stock Report on Sage Therapeutics
Sage Therapeutics Stock Up 2.1 %
SAGE stock traded up $0.11 during trading on Monday, reaching $5.28. The stock had a trading volume of 993,973 shares, compared to its average volume of 970,749. The company has a market capitalization of $322.98 million, a price-to-earnings ratio of -0.93 and a beta of 0.92. Sage Therapeutics has a one year low of $4.62 and a one year high of $28.26. The company's 50 day moving average is $6.70 and its two-hundred day moving average is $9.00.
Institutional Investors Weigh In On Sage Therapeutics
Large investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC grew its holdings in shares of Sage Therapeutics by 9.0% in the first quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company's stock worth $257,000 after purchasing an additional 1,130 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in Sage Therapeutics by 9.8% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,644 shares of the biopharmaceutical company's stock worth $312,000 after acquiring an additional 1,480 shares in the last quarter. Quest Partners LLC increased its position in shares of Sage Therapeutics by 14.5% during the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company's stock worth $128,000 after acquiring an additional 1,486 shares during the period. AdvisorShares Investments LLC raised its stake in shares of Sage Therapeutics by 13.6% during the second quarter. AdvisorShares Investments LLC now owns 16,030 shares of the biopharmaceutical company's stock valued at $177,000 after acquiring an additional 1,918 shares in the last quarter. Finally, Headlands Technologies LLC boosted its holdings in shares of Sage Therapeutics by 245.3% in the second quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company's stock valued at $43,000 after purchasing an additional 2,782 shares during the period. 99.22% of the stock is owned by institutional investors.
About Sage Therapeutics
(
Get Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Further Reading
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.